{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:00:51Z","timestamp":1790146851182,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"DOI":"10.1007\/s11845-026-04642-2","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:12:51Z","timestamp":1790143971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal serum uric acid trajectories and chronic kidney disease progression"],"prefix":"10.1007","author":[{"given":"Sumeyye","family":"Memis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murselin","family":"Guney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Engin","family":"Atay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-2914","authenticated-orcid":false,"given":"Ahmet","family":"Murt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"4642_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2011","unstructured":"Kovesdy CP (2011) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12:7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Suppl"},{"key":"4642_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12882-025-04028-Z","volume":"26","author":"J Guo","year":"1990","unstructured":"Guo J, Jiao W, Xia S and others (1990) The global, regional, and national patterns of change in the burden of chronic kidney disease from 1990 to 2021. BMC Nephrol 26:1\u201315. https:\/\/doi.org\/10.1186\/S12882-025-04028-Z","journal-title":"BMC Nephrol"},{"key":"4642_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K and others (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260\u2013272. https:\/\/doi.org\/10.1016\/S0140-6736(13)60687-X","journal-title":"Lancet"},{"key":"4642_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet 389:1238\u20131252. https:\/\/doi.org\/10.1016\/S0140-6736(16)32064-5","journal-title":"Lancet"},{"key":"4642_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR and others (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339\u2013352. https:\/\/doi.org\/10.1016\/S0140-6736(13)60595-4","journal-title":"Lancet"},{"key":"4642_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/JCM13030678","volume":"13","author":"F Mallamaci","year":"2024","unstructured":"Mallamaci F, Tripepi G (2024) Risk factors of chronic kidney disease progression: between old and new concepts. J Clin Med 13:678. https:\/\/doi.org\/10.3390\/JCM13030678","journal-title":"J Clin Med"},{"key":"4642_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-022-10118-X","volume":"12","author":"DLN Gon\u00e7alves","year":"2022","unstructured":"Gon\u00e7alves DLN, Moreira TR, da Silva LS (2022) A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease. Sci Rep 12:6251. https:\/\/doi.org\/10.1038\/S41598-022-10118-X","journal-title":"Sci Rep"},{"key":"4642_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/J.EKIR.2022.11.016","volume":"8","author":"RJ Johnson","year":"2023","unstructured":"Johnson RJ, Sanchez Lozada LG, Lanaspa MA et al (2023) Uric acid and chronic kidney disease: still more to do. Kidney Int Rep 8:229\u2013239. https:\/\/doi.org\/10.1016\/J.EKIR.2022.11.016","journal-title":"Kidney Int Rep"},{"key":"4642_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/CKJ\/SFZ136","volume":"14","author":"JT Kielstein","year":"2019","unstructured":"Kielstein JT, Heisterkamp M, Jing J and others (2019) Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. Clin Kidney J 14:277. https:\/\/doi.org\/10.1093\/CKJ\/SFZ136","journal-title":"Clin Kidney J"},{"issue":"1","key":"4642_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","volume":"9","author":"L Du","year":"2024","unstructured":"Du L, Zong Y, Li H and others (2024) Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):212. https:\/\/doi.org\/10.1038\/s41392-024-01916-y","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"4642_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/rheumatology\/kew2937498351","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda H (2017) Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 56(5):679\u2013688. https:\/\/doi.org\/10.1093\/rheumatology\/kew2937498351","journal-title":"Rheumatology (Oxford)"},{"key":"4642_CR12","doi-asserted-by":"publisher","DOI":"10.20517\/2574-1209.2021.11","volume":"5","author":"E Russo","year":"2021","unstructured":"Russo E, Verzola D, Cappadona F and others (2021) The role of uric acid in renal damage - a history of inflammatory pathways and vascular remodeling. Vessel Plus 5:15. https:\/\/doi.org\/10.20517\/2574-1209.2021.11","journal-title":"Vessel Plus"},{"key":"4642_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5817348","volume":"2020","author":"HY Su","year":"2020","unstructured":"Su HY, Yang C, Liang D, Liu HF (2020) Research advances in the mechanisms of hyperuricemia-induced renal injury. BioMed Res Int 2020:5817348. https:\/\/doi.org\/10.1155\/2020\/5817348","journal-title":"BioMed Res Int"},{"issue":"9","key":"4642_CR14","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D et al (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28(9):2221\u20132228. https:\/\/doi.org\/10.1093\/ndt\/gft029","journal-title":"Nephrol Dial Transplant"},{"issue":"17","key":"4642_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359(17):1811\u20131821. https:\/\/doi.org\/10.1056\/NEJMra0800885. (Erratum in: N Engl J Med. 2010 Jun 10;362(23):2235)","journal-title":"N Engl J Med"},{"issue":"1","key":"4642_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-020-01147-2","volume":"21","author":"T Lukkunaprasit","year":"2020","unstructured":"Lukkunaprasit T, Rattanasiri S, Turongkaravee S and others (2020) The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis. BMC Med Genet 21(1):210. https:\/\/doi.org\/10.1186\/s12881-020-01147-2","journal-title":"BMC Med Genet"},{"issue":"11","key":"4642_CR17","doi-asserted-by":"publisher","first-page":"e21108","DOI":"10.1016\/j.heliyon.2023.e21108","volume":"9","author":"S Wu","year":"2023","unstructured":"Wu S, Kong M, Song Y, Peng A (2023) Ethnic disparities in bidirectional causal effects between serum uric acid concentrations and kidney function: Trans-ethnic Mendelian randomization study. Heliyon 9(11):e21108. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21108","journal-title":"Heliyon"},{"key":"4642_CR18","doi-asserted-by":"publisher","unstructured":"Du L, Zong Y, Li H and others (2024) Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):212. https:\/\/doi.org\/10.1038\/s41392-024-01916-y","DOI":"10.1038\/s41392-024-01916-y"},{"key":"4642_CR19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/HJH.0B013E328337DA1D","volume":"28","author":"MA Yu","year":"2010","unstructured":"Yu MA, S\u00e1nchez-Lozada LG, Johnson RJ, Kang DH (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28:1234\u20131242. https:\/\/doi.org\/10.1097\/HJH.0B013E328337DA1D","journal-title":"J Hypertens"},{"issue":"5","key":"4642_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG et al (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38(5):1101\u20131106. https:\/\/doi.org\/10.1161\/hy1101.092839","journal-title":"Hypertension"},{"key":"4642_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/NDT\/GFM783","volume":"23","author":"LG S\u00e1nchez-Lozada","year":"2008","unstructured":"S\u00e1nchez-Lozada LG, Tapia E, Soto V and others (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23:1179\u20131185. https:\/\/doi.org\/10.1093\/NDT\/GFM783","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"4642_CR22","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr RP, Temml C, Gutjahr G et al (2008) Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19(12):2407\u20132413. https:\/\/doi.org\/10.1681\/ASN.2008010080","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4642_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","volume":"19","author":"DE Weiner","year":"2008","unstructured":"Weiner DE, Tighiouart H, Elsayed EF et al (2008) Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19(6):1204\u20131211. https:\/\/doi.org\/10.1681\/ASN.2007101075","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4642_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000326848","volume":"33","author":"H Sonoda","year":"2011","unstructured":"Sonoda H, Takase H, Dohi Y, Kimura G (2011) Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 33(4):352\u2013357. https:\/\/doi.org\/10.1159\/000326848","journal-title":"Am J Nephrol"},{"issue":"1","key":"4642_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0982-6","volume":"19","author":"M Ye","year":"2018","unstructured":"Ye M, Hu K, Jin J et al (2018) The association between time-mean serum uric acid levels and the incidence of chronic kidney disease in the general population: a retrospective study. BMC Nephrol 19(1):190. https:\/\/doi.org\/10.1186\/s12882-018-0982-6","journal-title":"BMC Nephrol"},{"issue":"6","key":"4642_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/nep.12679","volume":"22","author":"YP Hsieh","year":"2017","unstructured":"Hsieh YP, Chang CC, Yang Y et al (2017) The role of uric acid in chronic kidney disease patients. Nephrology (Carlton) 22(6):441\u2013448. https:\/\/doi.org\/10.1111\/nep.12679","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"4642_CR27","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/ndt\/gfv225","volume":"30","author":"H Nacak","year":"2015","unstructured":"Nacak H, van Diepen M, Qureshi AR and others (2015) Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with stage III, IV and V chronic kidney disease. Nephrol Dial Transplant 30(12):2039\u20132045. https:\/\/doi.org\/10.1093\/ndt\/gfv225","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"4642_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ndt\/gfx297","volume":"33","author":"CW Tsai","year":"2018","unstructured":"Tsai CW, Chiu HT, Huang HC et al (2018) Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses. Nephrol Dial Transplant 33(2):231\u2013241. https:\/\/doi.org\/10.1093\/ndt\/gfx297","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"4642_CR29","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1016\/j.ekir.2025.08.020","volume":"10","author":"Y Lee","year":"2025","unstructured":"Lee Y, Lipkowitz MS, Kopp JB et al (2025) Uric acid trajectories and CKD progression in the African American study of kidney disease and hypertension. Kidney Int Rep 10(11):3893\u20133904. https:\/\/doi.org\/10.1016\/j.ekir.2025.08.020","journal-title":"Kidney Int Rep"},{"issue":"26","key":"4642_CR30","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A and others (2020) Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382(26):2504\u20132513. https:\/\/doi.org\/10.1056\/NEJMoa1915833","journal-title":"N Engl J Med"},{"issue":"26","key":"4642_CR31","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria A, Galecki AT, Spino C and others (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382(26):2493\u20132503. https:\/\/doi.org\/10.1056\/NEJMoa1916624","journal-title":"N Engl J Med"},{"issue":"6","key":"4642_CR32","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S and others (2018) Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis 72(6):798\u2013810. https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.028","journal-title":"Am J Kidney Dis"},{"issue":"4S","key":"4642_CR33","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"9731","key":"4642_CR34","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M and others (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731):2073\u20132081. https:\/\/doi.org\/10.1016\/S0140-6736(10)60674-5","journal-title":"Lancet"},{"issue":"4","key":"4642_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M23-2814","volume":"177","author":"A Verma","year":"2024","unstructured":"Verma A, Schmidt IM, Claudel S et al (2024) Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria: a cohort study. Ann Intern Med 177(4):467\u2013475. https:\/\/doi.org\/10.7326\/M23-2814","journal-title":"Ann Intern Med"},{"issue":"1","key":"4642_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12882-022-02920-6","volume":"23","author":"W Pan","year":"2022","unstructured":"Pan W, Han Y, Hu H, He Y (2022) Association between hemoglobin and chronic kidney disease progression: a secondary analysis of a prospective cohort study in Japanese patients. BMC Nephrol 23(1):295. https:\/\/doi.org\/10.1186\/s12882-022-02920-6","journal-title":"BMC Nephrol"},{"issue":"2020","key":"4642_CR37","doi-asserted-by":"publisher","first-page":"7692376","DOI":"10.1155\/2020\/7692376","volume":"1","author":"E Palaka","year":"2020","unstructured":"Palaka E, Grandy S, van Haalen H et al (2020) The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. Int J Nephrol 1(2020):7692376. https:\/\/doi.org\/10.1155\/2020\/7692376","journal-title":"Int J Nephrol"},{"issue":"1","key":"4642_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO (2017) Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"4642_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ndt\/gfab184","volume":"37","author":"M Bozic","year":"2022","unstructured":"Bozic M, Diaz-Tocados JM, Bermudez-Lopez M and others (2022) Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant 37(4):663\u2013672. https:\/\/doi.org\/10.1093\/ndt\/gfab184","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"4642_CR40","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/ndt\/gfac212","volume":"38","author":"G D'Arrigo","year":"2023","unstructured":"D\u2019Arrigo G, Mallamaci F, Pizzini P et al (2023) CKD-MBD biomarkers and CKD progression: an analysis by the joint model. Nephrol Dial Transplant 38(4):932\u2013938. https:\/\/doi.org\/10.1093\/ndt\/gfac212","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"4642_CR41","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1093\/ndt\/gfq808","volume":"26","author":"CM O'Seaghdha","year":"2011","unstructured":"O\u2019Seaghdha CM, Hwang SJ, Muntner P et al (2011) Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 26(9):2885\u20132890. https:\/\/doi.org\/10.1093\/ndt\/gfq808","journal-title":"Nephrol Dial Transplant"},{"key":"4642_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1551390","volume":"16","author":"S Yang","year":"2025","unstructured":"Yang S, Hu Q, Liu K et al (2025) Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis. Front Pharmacol 16:1551390. https:\/\/doi.org\/10.3389\/fphar.2025.1551390","journal-title":"Front Pharmacol"},{"key":"4642_CR43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","volume":"26","author":"T Bardin","year":"2014","unstructured":"Bardin T, Richette P (2014) Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 26:186\u2013191. https:\/\/doi.org\/10.1097\/BOR.0000000000000028","journal-title":"Curr Opin Rheumatol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04642-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-026-04642-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04642-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:12:52Z","timestamp":1790143972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-026-04642-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":43,"alternative-id":["4642"],"URL":"https:\/\/doi.org\/10.1007\/s11845-026-04642-2","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None declared.","order":1,"name":"Ethics","label":"Conflicts of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}